What question did this study set out to answer?

Assess the cost-effectiveness of the ezetimibe-atorvastatin single-pill combination compared to free combination therapy in Chinese adults with hypercholesterolemia.

June 11, 2026Journal of Medical EconomicsOpen Access

Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia

Q: What is the clinical evidence from this study?

Population: Hypercholesterolemia (n=311242). Intervention: Ezetimibe-atorvastatin single-pill combination vs. Ezetimibe-atorvastatin free combination therapy. Primary outcome: Incremental cost-effectiveness ratio (ICER) (ICER USD 4,070/QALY).

View Full Paper

Ask AI

Bookmark

Key result

Ezetimibe-atorvastatin single-pill combination proves cost-effective vs free combination therapy at ~$4,070 per QALY gained.

ICER USD 4,070/QALY
n=311,242

Why the study?

Does ezetimibe-atorvastatin single-pill combination improve cost-effectiveness compared to free combination therapy in Chinese adults with hypercholesterolemia?

Key Points

Assess the cost-effectiveness of the ezetimibe-atorvastatin single-pill combination compared to free combination therapy in Chinese adults with hypercholesterolemia.
Conducted a budget impact analysis over 5 years estimating the adoption of ezetimibe-atorvastatin SPC
Analyzed costs and outcomes using a population of 311,242 Chinese adults
Performed subgroup analyses by age, sex, and cardiovascular risk.
E/A SPC yielded an additional 0.06 QALYs at an incremental cost of USD 250.12, leading to an ICER of USD 4,070/QALY
Probability of cost-effectiveness for E/A SPC was 91%
Over 5 years, incremental drug spending was USD 372.5 million, with USD 292.0 million in avoided cardiovascular event costs.

Structured PICO

Does ezetimibe-atorvastatin single-pill combination improve cost-effectiveness compared to free combination therapy in Chinese adults with hypercholesterolemia?

Population

311,242 Chinese adults with hypercholesterolemia inadequately controlled on statin monotherapy, evaluated in a cost-effectiveness and 5-year budget impact analysis.

Intervention

Ezetimibe-atorvastatin single-pill combination (E/A SPC)

Comparator

Ezetimibe and atorvastatin free combination therapy (E/A FCT)

Outcome

Cost-effectiveness (incremental cost-effectiveness ratio, ICER) and 5-year budget impact

Main Result

Effect estimate: ICER USD 4,070/QALY

Limitations

The study findings should be further validated using larger-scale real-world data from China.
Findings should be further validated using larger-scale real-world data from China

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Ezetimibe-atorvastatin single-pill combination is a cost-effective strategy compared to free combination therapy for Chinese adults with hypercholesterolemia, supporting its inclusion in the National Reimbursement Drug List.

Cite This Study

Xing et al. (2026) studied Hypercholesterolemia (n=311,242). Ezetimibe-atorvastatin single-pill combination vs. Ezetimibe-atorvastatin free combination therapy was evaluated on Incremental cost-effectiveness ratio (ICER) (ICER USD 4,070/QALY). Ezetimibe-atorvastatin single-pill combination was cost-effective compared to free combination therapy, generating 0.06 additional QALYs with an ICER of USD 4,070/QALY.

synapsesocial.com/papers/6a2a52ae80c8f91e7f39e9e6 https://doi.org/10.1080/13696998.2026.2682693

View Full Paper

Ask AI

Bookmark

Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia

Key Points

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia

Key Points

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider